SCNX launches first product ARBLI™, acquires REZENOPY™, divests legacy units to focus on pharma

Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 26, 2025 · ~2 min read

Key Changes

• high

  Launched ARBLI™ (losartan oral suspension) in Q3 2025 following March FDA approval, generating $432K revenue (up 216% YoY) at 76.8% gross margin vs. 4.4% prior year. Second product REZENOPY™ (naloxone nasal spray) expected to launch Q2 2026.

  Business: ARBLI™ commercial launch verify on EDGAR →
• high

  Divested legacy pharmaceutical distribution and telehealth subsidiaries (IPS, Softell, Bonum) to Tollo Health (affiliated with former CEO and COO) in April 2025, completing strategic pivot to specialty pharma. Company now owns only Scienture LLC.

  Business: IPS/Softell/Bonum divestitures verify on EDGAR →
• high

  Working capital improved from $(1.6)M deficit to $5.2M surplus; cash increased from $308K to $6.7M; going-concern doubt removed. Improvement driven by $26.3M equity raise during 2025, partially offset by $26.3M non-cash impairment charges (goodwill and IPR&D).

  MD&A: Working capital improvement verify on EDGAR →